Safety and Efficacy of an Inactivated and Non Adjuvanted Vaccine Against Influenza A in Renal Transplant Recipients

Inclusion criteria: * Age \> 18 and \< 60 years old * Signed information consent * Social security coverage * Renal transplantation \> 6 months with a creatinine clearance \> 20 ml/mn * Stable renal function defined as serum creatinine variation \< 20 % for the last three months * Receiving a triple immunosuppression regimen including steroids, Calcineurine inhibitors (cyclosporine or Tacrolimus), and IMPDH inhibitors (Mycophenolate Mofetil or mycophenolic acid) * Regular follow-up For child bearing aged female: * Negative urinary HCG * Contraception during the first three months of the study Exclusion criteria: * Poor renal function defined as creatinine clairance \< 20 ml/mn * Unstable renal function defined as serum creatinine variations \> 20 % during the last 3 months * Cellular or humoral acute rejection episode during the last 3 months before inclusion * Known HIV, HBV or HCV infection * Other vaccine administered during the last 3 weeks before inclusion or scheduled in the month after the second vaccine injection * Known allergy to egg proteins or to one the vaccine compounds * Severe adverse events after prior administration of any influenza vaccine * Multiple sclerosis * Past history of Guillain Barre syndrome * Fever at inclusion * H1N1 influenza episode with positive virological tests during the last 6 months * Contact with people infected with H1N1 influenza during the week prior to inclusion * Cancer requiring radiotherapy or chemotherapy during the last 6 months * Blood transfusion during the last 3 months * Pregnancy during the last 3 months * No follow-up